Cribstone Capital Management LLC decreased its position in shares of Amgen Inc. (NASDAQ:AMGN) by 3.9% during the second quarter, according to its most recent disclosure with the SEC. The fund owned 1,070 shares of the medical research company’s stock after selling 43 shares during the period. Cribstone Capital Management LLC’s holdings in Amgen were worth $184,000 as of its most recent SEC filing.
Other large investors also recently made changes to their positions in the company. Norges Bank acquired a new position in Amgen during the fourth quarter valued at approximately $1,016,913,000. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main acquired a new position in Amgen during the fourth quarter valued at approximately $275,209,000. Skandinaviska Enskilda Banken AB publ acquired a new position in Amgen during the first quarter valued at approximately $110,402,000. Swiss National Bank raised its position in Amgen by 26.5% in the first quarter. Swiss National Bank now owns 2,636,008 shares of the medical research company’s stock valued at $432,490,000 after buying an additional 551,600 shares during the last quarter. Finally, Bank of Nova Scotia raised its position in Amgen by 414.4% in the first quarter. Bank of Nova Scotia now owns 601,862 shares of the medical research company’s stock valued at $98,747,000 after buying an additional 484,868 shares during the last quarter. Institutional investors and hedge funds own 79.53% of the company’s stock.
Amgen Inc. (NASDAQ AMGN) opened at 173.69 on Wednesday. The stock has a 50 day moving average of $173.87 and a 200-day moving average of $166.86. Amgen Inc. has a one year low of $133.64 and a one year high of $184.21. The firm has a market capitalization of $126.74 billion, a PE ratio of 15.82 and a beta of 1.35.
Amgen (NASDAQ:AMGN) last announced its quarterly earnings data on Tuesday, July 25th. The medical research company reported $3.27 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $3.11 by $0.16. Amgen had a return on equity of 29.85% and a net margin of 35.46%. The firm had revenue of $5.81 billion for the quarter, compared to analysts’ expectations of $5.67 billion. During the same period last year, the business posted $2.84 earnings per share. The firm’s revenue for the quarter was up 2.1% on a year-over-year basis. On average, equities analysts predict that Amgen Inc. will post $12.57 EPS for the current year.
The company also recently disclosed a quarterly dividend, which will be paid on Friday, September 8th. Investors of record on Thursday, August 17th will be paid a dividend of $1.15 per share. This represents a $4.60 annualized dividend and a yield of 2.65%. The ex-dividend date is Tuesday, August 15th. Amgen’s dividend payout ratio (DPR) is presently 41.93%.
ILLEGAL ACTIVITY WARNING: “Amgen Inc. (NASDAQ:AMGN) Shares Sold by Cribstone Capital Management LLC” was first posted by BBNS and is the property of of BBNS. If you are reading this story on another domain, it was illegally stolen and reposted in violation of United States and international copyright legislation. The correct version of this story can be accessed at https://baseballnewssource.com/markets/amgen-inc-nasdaqamgn-shares-sold-by-cribstone-capital-management-llc-updated/1312945.html.
Several research analysts have recently commented on AMGN shares. Cowen and Company reissued an “outperform” rating and issued a $209.00 price objective on shares of Amgen in a research note on Wednesday, April 19th. Sanford C. Bernstein reissued a “market perform” rating and issued a $178.00 price objective on shares of Amgen in a research note on Tuesday, April 25th. Robert W. Baird reissued a “neutral” rating and issued a $165.00 price objective on shares of Amgen in a research note on Friday, April 28th. Mizuho set a $195.00 price objective on shares of Amgen and gave the company a “buy” rating in a research note on Saturday, May 6th. Finally, Oppenheimer Holdings, Inc. set a $189.00 price objective on shares of Amgen and gave the company a “buy” rating in a research note on Tuesday, May 9th. One analyst has rated the stock with a sell rating, twelve have assigned a hold rating, twelve have given a buy rating and two have given a strong buy rating to the stock. Amgen currently has a consensus rating of “Buy” and an average price target of $186.64.
In related news, SVP Cynthia M. Patton sold 2,922 shares of the firm’s stock in a transaction on Wednesday, May 24th. The stock was sold at an average price of $154.40, for a total transaction of $451,156.80. Following the transaction, the senior vice president now directly owns 24,214 shares in the company, valued at $3,738,641.60. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 0.20% of the company’s stock.
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with our FREE daily email newsletter.